Assembly Biosciences (ASMB) News Today $9.47 +0.08 (+0.85%) As of 04:00 PM Eastern Add Compare Share Share Headlines Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrendsBuy This Stock All Sources Trusted Sources MarketBeat Benzinga Bloomberg GuruFocus MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha TalkMarkets The Street TipRanks The Wall Street Journal Wall Street Zen Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent April 2025 March 2025 February 2025 January 2025 December 2024 November 2024 October 2024 September 2024 August 2024 July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 May 2023 April 2023 March 2023 February 2023 January 2023 December 2022 November 2022 October 2022 September 2022 August 2022 July 2022 June 2022 May 2022 Time Period HC Wainwright Issues Optimistic Forecast for ASMB EarningsMarch 28, 2025 | americanbankingnews.comResearch Analysts Set Expectations for ASMB Q1 EarningsAssembly Biosciences, Inc. (NASDAQ:ASMB - Free Report) - Stock analysts at HC Wainwright upped their Q1 2025 earnings per share estimates for shares of Assembly Biosciences in a research note issued on Monday, March 24th. HC Wainwright analyst E. Arce now forecasts that the biopharmaceutical compMarch 27, 2025 | marketbeat.comAssembly Biosciences (NASDAQ:ASMB) Coverage Initiated at GuggenheimMarch 27, 2025 | americanbankingnews.comAssembly Biosciences initiated with a Buy at GuggenheimMarch 26, 2025 | markets.businessinsider.comAssembly Biosciences (NASDAQ:ASMB) Coverage Initiated by Analysts at GuggenheimGuggenheim initiated coverage on shares of Assembly Biosciences in a research report on Tuesday. They set a "buy" rating and a $31.00 price target on the stock.March 26, 2025 | marketbeat.comFY2029 Earnings Estimate for ASMB Issued By HC WainwrightAssembly Biosciences, Inc. (NASDAQ:ASMB - Free Report) - HC Wainwright issued their FY2029 earnings per share estimates for Assembly Biosciences in a report released on Monday, March 24th. HC Wainwright analyst E. Arce expects that the biopharmaceutical company will post earnings of ($12.58) perMarch 26, 2025 | marketbeat.comGuggenheim starts Assembly Biosciences with a Buy ahead of clinical readoutsMarch 26, 2025 | markets.businessinsider.comGuggenheim Initiates Coverage of Assembly Biosciences (ASMB) with Buy RecommendationMarch 26, 2025 | msn.comBrokers Set Expectations for ASMB FY2029 EarningsMarch 26, 2025 | americanbankingnews.comAssembly Biosciences (NASDAQ:ASMB) Rating Lowered to Hold at StockNews.comMarch 26, 2025 | americanbankingnews.comHC Wainwright Reaffirms "Neutral" Rating for Assembly Biosciences (NASDAQ:ASMB)March 26, 2025 | americanbankingnews.comAssembly Biosciences (NASDAQ:ASMB) Lowered to Hold Rating by StockNews.comStockNews.com lowered Assembly Biosciences from a "buy" rating to a "hold" rating in a report on Monday.March 25, 2025 | marketbeat.comAssembly Biosciences' (ASMB) Neutral Rating Reiterated at HC WainwrightHC Wainwright reaffirmed a "neutral" rating on shares of Assembly Biosciences in a research report on Monday.March 25, 2025 | marketbeat.comAssembly Biosciences (NASDAQ:ASMB) Announces Quarterly Earnings Results, Beats Expectations By $0.55 EPSAssembly Biosciences (NASDAQ:ASMB - Get Free Report) announced its earnings results on Thursday. The biopharmaceutical company reported ($1.57) earnings per share for the quarter, topping analysts' consensus estimates of ($2.12) by $0.55. Assembly Biosciences had a negative net margin of 144.05% and a negative return on equity of 121.46%.March 21, 2025 | marketbeat.comAssembly Biosciences files $250M mixed securities shelfMarch 21, 2025 | markets.businessinsider.comAssembly Biosciences Reports Year End 2024 Financial Results and Recent HighlightsMarch 20, 2025 | globenewswire.comAssembly Biosciences, Inc. (NASDAQ:ASMB) Sees Significant Increase in Short InterestAssembly Biosciences, Inc. (NASDAQ:ASMB - Get Free Report) was the recipient of a large growth in short interest during the month of February. As of February 28th, there was short interest totalling 20,300 shares, a growth of 18.0% from the February 13th total of 17,200 shares. Currently, 0.6% of the shares of the stock are short sold. Based on an average daily trading volume, of 30,300 shares, the short-interest ratio is presently 0.7 days.March 20, 2025 | marketbeat.comAssembly Biosciences (ASMB) to Release Earnings on ThursdayAssembly Biosciences (NASDAQ:ASMB) will be releasing earnings before the market opens on Thursday, March 27, Financial Modeling Prep reports.March 20, 2025 | marketbeat.comMonimus Capital Management LP Takes $664,000 Position in Assembly Biosciences, Inc. (NASDAQ:ASMB)Monimus Capital Management LP purchased a new stake in Assembly Biosciences, Inc. (NASDAQ:ASMB - Free Report) in the 4th quarter, according to the company in its most recent 13F filing with the SEC. The fund purchased 42,067 shares of the biopharmaceutical company's stock, valued at approximately $March 16, 2025 | marketbeat.comAssembly Biosciences, Inc. (NASDAQ:ASMB) Short Interest Up 25.5% in FebruaryAssembly Biosciences, Inc. (NASDAQ:ASMB - Get Free Report) saw a large growth in short interest in February. As of February 15th, there was short interest totalling 17,200 shares, a growth of 25.5% from the January 31st total of 13,700 shares. Approximately 0.5% of the company's stock are short sold. Based on an average daily volume of 33,700 shares, the days-to-cover ratio is currently 0.5 days.March 5, 2025 | marketbeat.comIs Assembly Biosciences, Inc. (ASMB) Among Stocks With At Least $20 Million In Insider Spending Recently?March 4, 2025 | insidermonkey.comAssembly Biosciences doses first participant in Phase 1a study of ABI-6250February 26, 2025 | markets.businessinsider.comAssembly Biosciences Doses First Participant in Phase 1a Clinical Study of Oral Entry Inhibitor Candidate ABI-6250 for Hepatitis Delta VirusFebruary 26, 2025 | globenewswire.comAssembly Biosciences reports positive Phase 1a results in genital herpesFebruary 20, 2025 | markets.businessinsider.comAssembly Biosciences Reports Positive Interim Phase 1a Results from Clinical Trial Evaluating Long-Acting Helicase-Primase Inhibitor ABI-1179 in Development for Recurrent Genital HerpesFebruary 20, 2025 | globenewswire.com62,970 Shares in Assembly Biosciences, Inc. (NASDAQ:ASMB) Purchased by Peapod Lane Capital LLCPeapod Lane Capital LLC bought a new stake in Assembly Biosciences, Inc. (NASDAQ:ASMB - Free Report) in the 4th quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The fund bought 62,970 shares of the biopharmaceutical company's stock, vFebruary 13, 2025 | marketbeat.comAssembly Biosciences (NASDAQ:ASMB) Stock Price Passes Above 200-Day Moving Average - Here's What HappenedAssembly Biosciences (NASDAQ:ASMB) Shares Pass Above 200-Day Moving Average - What's Next?January 8, 2025 | marketbeat.comMichael Houghton Buys 3,202 Shares of Assembly Biosciences, Inc. (NASDAQ:ASMB) StockJanuary 1, 2025 | insidertrades.comAssembly Biosciences, Inc. (NASDAQ:ASMB) Director Buys $49,983.22 in StockAssembly Biosciences, Inc. (NASDAQ:ASMB - Get Free Report) Director Michael Houghton bought 3,202 shares of the business's stock in a transaction that occurred on Monday, December 30th. The shares were acquired at an average price of $15.61 per share, with a total value of $49,983.22. Following the completion of the transaction, the director now directly owns 3,202 shares of the company's stock, valued at $49,983.22. This trade represents a ∞ increase in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link.December 31, 2024 | marketbeat.comAssembly Biosciences, Inc. (NASDAQ:ASMB) Short Interest UpdateAssembly Biosciences, Inc. (NASDAQ:ASMB - Get Free Report) saw a significant drop in short interest during the month of December. As of December 15th, there was short interest totalling 13,300 shares, a drop of 16.4% from the November 30th total of 15,900 shares. Approximately 0.3% of the company's stock are short sold. Based on an average daily trading volume, of 33,400 shares, the days-to-cover ratio is presently 0.4 days.December 29, 2024 | marketbeat.comH.C. Wainwright stays Neutral on Assembly Biosciences after ABI-4334 dataDecember 27, 2024 | markets.businessinsider.comH.C. Wainwright Sticks to Its Hold Rating for Assembly Biosciences (ASMB)December 27, 2024 | markets.businessinsider.comAssembly Biosciences (NASDAQ:ASMB) Receives "Neutral" Rating from HC WainwrightHC Wainwright reiterated a "neutral" rating on shares of Assembly Biosciences in a report on Friday.December 27, 2024 | marketbeat.comAssembly Biosciences Shares Rise on Results from Hepatitis B Drug TrialDecember 26, 2024 | marketwatch.comAssembly Biosciences Announces Encouraging Phase 1b Data For ABI-4334 In Chronic Hepatitis BDecember 26, 2024 | markets.businessinsider.comAssembly Biosciences announces interim PK, efficacy from Phase 1b studyDecember 26, 2024 | markets.businessinsider.comAssembly Bio spikes after early-stage data for Gilead-partnered Hep B therapyDecember 26, 2024 | seekingalpha.comAssembly Biosciences Reports Interim Phase 1b Results from Clinical Trial Evaluating Next-Generation Capsid Assembly Modulator Candidate ABI-4334 in Chronic Hepatitis BDecember 26, 2024 | globenewswire.comAssembly Biosciences (NASDAQ:ASMB) Stock Price Crosses Above Two Hundred Day Moving Average - Here's What HappenedAssembly Biosciences (NASDAQ:ASMB) Share Price Crosses Above Two Hundred Day Moving Average - Time to Sell?December 21, 2024 | marketbeat.comAssembly Bio Receives Total $30.1 Mln As Equity Investment, Funding From Gilead, Stock UpDecember 20, 2024 | markets.businessinsider.comAssembly Biosciences Shares Rise 19% After Gilead Investment, FundingDecember 20, 2024 | marketwatch.comAssembly Biosciences Gets $30.1M Equity Investment, Funding From GileadDecember 19, 2024 | marketwatch.comAssembly Biosciences Announces $30.1 Million Equity Investment and Accelerated Funding from Gilead to Advance Clinical Development ProgramsDecember 19, 2024 | markets.businessinsider.comAssembly Biosciences, Inc. (NASDAQ:ASMB) Sees Significant Growth in Short InterestAssembly Biosciences, Inc. (NASDAQ:ASMB - Get Free Report) saw a significant growth in short interest in November. As of November 30th, there was short interest totalling 15,900 shares, a growth of 37.1% from the November 15th total of 11,600 shares. Based on an average daily volume of 33,200 shares, the days-to-cover ratio is currently 0.5 days. Currently, 0.4% of the shares of the stock are sold short.December 13, 2024 | marketbeat.comSouth Korea's National Assembly votes to impeach the national police chief and the justice minister over martial lawDecember 12, 2024 | abcnews.go.comAssembly Biosciences, Inc. (NASDAQ:ASMB) Sees Large Increase in Short InterestAssembly Biosciences, Inc. (NASDAQ:ASMB - Get Free Report) was the target of a large growth in short interest in the month of November. As of November 15th, there was short interest totalling 11,600 shares, a growth of 45.0% from the October 31st total of 8,000 shares. Based on an average daily trading volume, of 30,500 shares, the short-interest ratio is presently 0.4 days. Currently, 0.3% of the shares of the company are short sold.November 29, 2024 | marketbeat.comAssembly Biosciences Reports Q3 2024 Financials and Strategic AdvancesNovember 22, 2024 | markets.businessinsider.comWhat is HC Wainwright's Forecast for ASMB FY2024 Earnings?Assembly Biosciences, Inc. (NASDAQ:ASMB - Free Report) - HC Wainwright boosted their FY2024 earnings estimates for shares of Assembly Biosciences in a research report issued to clients and investors on Monday, November 11th. HC Wainwright analyst E. Arce now forecasts that the biopharmaceutical cNovember 14, 2024 | marketbeat.comBearish: Analysts Just Cut Their Assembly Biosciences, Inc. (NASDAQ:ASMB) Revenue and EPS estimatesNovember 14, 2024 | finance.yahoo.comIPS outlines priorities for 2025 General Assembly sessionNovember 12, 2024 | msn.com Remove Ads Get Assembly Biosciences News Delivered to You Automatically Sign up to receive the latest news and ratings for ASMB and its competitors with MarketBeat's FREE daily newsletter. Email Address ASMB Media Mentions By Week ASMB Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. ASMB News Sentiment▼0.540.58▲Average Medical News Sentiment ASMB News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. ASMB Articles This Week▼88▲ASMB Articles Average Week Remove Ads Get Assembly Biosciences News Delivered to You Automatically Sign up to receive the latest news and ratings for ASMB and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies Nektar Therapeutics News Cumberland Pharmaceuticals News Eli Lilly and Company News Johnson & Johnson News AbbVie News Merck & Co., Inc. News Pfizer News Bristol-Myers Squibb News Zoetis News Royalty Pharma News Headlines Tools Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:ASMB) was last updated on 4/2/2025 by MarketBeat.com Staff From Our PartnersTrump Allies Confirm Exec Order 14024 Triggers Dollar CollapseExecutive Order 14024 is paving the way for irreversible damage to the dollar's value—threatening your wealth,...Priority Gold | SponsoredTrump Orders 'National Digital Asset Stockpile'‘Digital Asset Reserve’ for THIS Coin??? Get all the details before this story gains even more tractionCrypto 101 Media | Sponsored“Fed Proof” Your Bank Account with THESE 4 Simple StepsStarting as soon as a few months from now, the United States government will make a sweeping change to bank ac...Weiss Ratings | Sponsored“Amazon Coin” set to outperform BitcoinChris Rowe – the man who recommended Amazon in 1998… Bitcoin and Ethereum in 2017… And has spotted 44 diffe...True Market Insiders | SponsoredMost gold “analysts” aren’t really gold analysts… [watch out]People who don’t understand the gold market are about to lose a lot of money. Unfortunately, most so-called “g...Golden Portfolio | SponsoredA market crash is coming—here’s whenThe stock market cycle I've used to identify the most likely day of the next market crash is the exact same in...Chaikin Analytics | SponsoredUrgent Bitcoin alert for RIGHT NOWFormer billion-dollar hedge fund manager Larry Benedict has released the most incredible presentation of his 4...Brownstone Research | SponsoredTrump’s Secret WeaponPlease don't wait—this is your moment to take action. Download your Wealth Protection Guide now, claim your fr...American Alternative | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Assembly Biosciences, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Assembly Biosciences With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Buy ASMB Stock Free ASMB Stock Alerts